64 related articles for article (PubMed ID: 277249)
1. Prolonged metronidazole administration with protracted radiotherapy: a pilot study on response of advanced tumours.
Karim AB
Br J Cancer Suppl; 1978 Jun; 3():299-301. PubMed ID: 277249
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with misonidazole.
Dische S; Saunders MI
Br J Cancer Suppl; 1978 Jun; 3():311-3. PubMed ID: 277252
[TBL] [Abstract][Full Text] [Related]
3. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Dische S; Saunders MI; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of hyperfractionated accelerated radiation and simultaneous Carboplatin therapy for advanced head and neck carcinomas.
Schnabel T; Zamboglou N; Kolotas C; Jiménez W; Strehl H; Schmitt G
Strahlenther Onkol; 1992 Jun; 168(6):318-21. PubMed ID: 1621209
[TBL] [Abstract][Full Text] [Related]
5. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of the radiosensitizer cisplatin. A pilot study].
Klima A; Szepesi S
Laryngol Rhinol Otol (Stuttg); 1987 Sep; 66(9):457-9. PubMed ID: 3683038
[TBL] [Abstract][Full Text] [Related]
7. Dynamic dose-fractionation combined with oxygen breathing at ambient pressure and high-dose metronidazole in head and neck, and uterine cervix cancer.
Siracká E; Kubovcáková N; Durkovský J; Jancina J; Boljesíková E
Neoplasma; 1983; 30(6):725-31. PubMed ID: 6656969
[TBL] [Abstract][Full Text] [Related]
8. Taxol plus radiation for head and neck cancer.
Rosenthal DI; Carbone DP
J Infus Chemother; 1995; 5(2):46-54. PubMed ID: 8521234
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
10. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
[TBL] [Abstract][Full Text] [Related]
12. [Chemoradiotherapy for patients with advanced head and neck cancer].
Tsukuda M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2049-57. PubMed ID: 9388513
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck.
Conley B; Jacobs M; Suntharalingam M; Zacharski D; Ord RA; Gray W; Aisner J
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-78-S2-80. PubMed ID: 9045343
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Budach W; Hehr T; Budach V; Belka C; Dietz K
BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.
Wijffels KI; Marres HA; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH
Oral Oncol; 2008 Apr; 44(4):335-44. PubMed ID: 17689286
[TBL] [Abstract][Full Text] [Related]
17. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.
Marcial VA; Pajak TF; Kramer S; Davis LW; Stetz J; Laramore GE; Jacobs JR; Al-Sarraf M; Brady LW
Semin Oncol; 1988 Feb; 15(1):39-60. PubMed ID: 3278390
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells.
Urtasun RC; Chapman JD; Band P; Rabin HR; Fryer CG; Sturmwind J
Radiology; 1975 Oct; 117(1):129-33. PubMed ID: 1162051
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
20. Safety of nitroimidazoles.
Roe FJ
Scand J Infect Dis Suppl; 1985; 46():72-81. PubMed ID: 3865353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
